PVI
FHTX icon

Pura Vida Investments’s Foghorn Therapeutics FHTX Stock Holding History

Pura Vida Investments’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-68,095
Closed -$949K – 262
2021
Q3 		$949K Buy
+68,095
New +$754K 0.03% 223

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pura Vida Investments's FHTX Position: Q4 2021 in Review

Pura Vida Investments sold out of Foghorn Therapeutics (FHTX) in Q4 2021, closing a stake of 68,095 shares — an estimated $949K sold.

Pura Vida Investments first reported a position in FHTX in Q3 2021 and held it in 1 quarter. The position peaked at $949K in Q3 2021. 60 funds tracked by Wall St. Rank hold FHTX as of Q4 2021.

  • Pura Vida Investments reported no remaining Foghorn Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Pura Vida Investments sold 68,095 Foghorn Therapeutics shares in Q4 2021, an estimated $949K.
  • Pura Vida Investments first reported a position in Foghorn Therapeutics in Q3 2021 and held it in 1 quarter.
  • Pura Vida Investments's Foghorn Therapeutics position peaked at $949K in Q3 2021.
  • 60 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q4 2021.

Based on Pura Vida Investments's 13F filing for Q4 2021, filed 14 Feb 2022.